A Single and Multiple Ascending Dose Study of Subcutaneously Administered JNJ-75220795
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT04844450 |
Recruitment Status :
Completed
First Posted : April 14, 2021
Last Update Posted : August 18, 2023
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Fatty Liver Disease | Drug: JNJ-75220795 Drug: Placebo | Phase 1 |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 55 participants |
Allocation: | Randomized |
Intervention Model: | Sequential Assignment |
Masking: | Double (Participant, Investigator) |
Primary Purpose: | Treatment |
Official Title: | A Double-Blind, Placebo-Controlled, Randomized, Multipart, Single and Multiple Ascending Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Subcutaneously Administered JNJ-75220795 |
Actual Study Start Date : | April 29, 2021 |
Actual Primary Completion Date : | March 31, 2023 |
Actual Study Completion Date : | March 31, 2023 |
Arm | Intervention/treatment |
---|---|
Experimental: Single Ascending Dose (SAD)
Participants in cohorts 1-5 and cohorts 3a-5a will receive subcutaneous (SC) injection of single dose (Part A) of JNJ-75220795 or matching placebo.
|
Drug: JNJ-75220795
JNJ-75220795 will be administered subcutaneously. Drug: Placebo Matching placebo will be administered subcutaneously. |
Experimental: Multiple Ascending Dose (MAD)
Participants in cohorts 6-8 will receive SC injection of 2 doses (Part B) of JNJ-75220795 or matching placebo. Participants in cohorts 9-11 will receive SC injection of 4 doses (Part C) of JNJ-75220795 or matching placebo.
|
Drug: JNJ-75220795
JNJ-75220795 will be administered subcutaneously. Drug: Placebo Matching placebo will be administered subcutaneously. |
- Number of Participants With Treatment-Emergent Signs and Symptoms/ Adverse Events (AEs) [ Time Frame: Up to Day 182 ]Number of participants with treatment-emergent signs and symptoms/adverse events (including allergic reactions/hypersensitivity and local injection site reactions) will be reported. An AE is any untoward medical occurrence in a participant participating in a clinical study that does not necessarily have a causal relationship with the pharmaceutical/biological agent under study. Treatment-emergent adverse events (TEAEs) are defined as AEs with onset or worsening on or after date of first dose of study treatment.
- Number of Participants With Change From Baseline in Vital Signs Abnormalities [ Time Frame: Baseline, up to Day 168 ]Number of participants with change from baseline in vital signs abnormalities including temperature, heart rate, respiratory rate, and blood pressure (supine) will be reported.
- Number of Participants With Change From Baseline in Clinical Laboratory Abnormalities [ Time Frame: Baseline, up to Day 168 ]Number of participants with change from baseline in clinical laboratory abnormalities including hematology, chemistry and urinalysis will be reported.
- Number of Participants With Change From Baseline in Physical Examination Abnormalities [ Time Frame: Baseline, up to Day 168 ]Number of participants with change from baseline in physical examination abnormalities will be reported.
- Number of Participants With Change From Baseline in Electrocardiogram (ECG) Abnormalities [ Time Frame: Baseline, up to Day 168 ]Number of participants with change from baseline in ECG abnormalities will be reported.
- Percent Change From Baseline in Liver Fat Content [ Time Frame: Baseline, weeks 6, 12, 18 and 24 ]Percent change from baseline in liver fat content will be reported.
- Plasma Concentration of JNJ-75220795 Over Time [ Time Frame: SAD: Predose, up to Day 3 and MAD: Predose, up to Day 86 ]Plasma samples will be analyzed to determine concentrations of JNJ-75220795.
- Percentage of Participants With Treatment-emergent Anti Drug Antibodies (ADA) [ Time Frame: Up to Day 168 ]Percentage of participants with treatment-emergent ADA will be assessed using a validated assay for ADA analysis.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years to 65 Years (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Participants with certain genetic predisposition to non-alcoholic fatty liver disease (NAFLD) determined at screening
- Presence of liver steatosis at screening
- Participants on anti-hypertensive and/or lipid lowering medications and/or glucose lowering medications must be on stable dose(s) for at least 4 weeks prior to screening
- Weight stable defined as no more than 5% body weight loss or gain within 3 months prior to screening and no more than 5% body weight loss or gain from screening to randomization
Exclusion Criteria:
- Known allergies, hypersensitivity, or intolerance to JNJ-75220795 or its excipients
- History of hepatitis B surface antigen (HbsAg) or hepatitis C antibody (anti-HCV) positive, or other clinically active liver disease, or tests positive for HbsAg or anti-HCV at screening
- History of human immunodeficiency virus (HIV) antibody positive, or tests positive for HIV at screening
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04844450
United States, Florida | |
Research Centers of America, LLC | |
Hollywood, Florida, United States, 33024 | |
United States, Texas | |
Endeavor Clinical Trials, LLC | |
San Antonio, Texas, United States, 78240 |
Study Director: | Janssen Research & Development, LLC Clinical Trial | Janssen Research & Development, LLC |
Responsible Party: | Janssen Research & Development, LLC |
ClinicalTrials.gov Identifier: | NCT04844450 |
Other Study ID Numbers: |
CR108997 75220795NAS1001 ( Other Identifier: Janssen Research & Development, LLC ) |
First Posted: | April 14, 2021 Key Record Dates |
Last Update Posted: | August 18, 2023 |
Last Verified: | August 2023 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | Yes |
Plan Description: | The data sharing policy of the Janssen Pharmaceutical Companies of Johnson & Johnson is available at www.janssen.com/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu |
URL: | https://www.janssen.com/clinical-trials/transparency |
Studies a U.S. FDA-regulated Drug Product: | Yes |
Studies a U.S. FDA-regulated Device Product: | No |
Liver Diseases Fatty Liver Digestive System Diseases |